OSTX net incomeQ2 2026-$8.63M
OSTX net income was -$8.63M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.54M a year earlier. For the full fiscal 2025 it was -$28.75M, compared with -$8.88M in fiscal 2024.
OS Therapies Incorporated (OSTX) financials
For the twelve months ended Jun 30, 2026, OS Therapies Incorporated reported -$39.37M of net income.
- Net income, TTM
- -$39.37M
- Cash
- $205.0K
- Market cap
- $52.0M
FY2023FY2025
OSTX revenue and earnings growth
OSTX EPSQ2 2026-$0.20
OSTX diluted EPS was -$0.20 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.98.
OSTX free cash flowQ4 2025-$3.73M
OSTX free cash flow was -$3.73M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$14.70M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $16.36M | $2.84M | $3.22M |
| Selling, general and admin | $12.34M | $3.97M | $1.13M |
| Operating income | -$28.71M | -$6.81M | -$4.34M |
| Interest expense | - | $2.05M | $3.45M |
| Net income | -$28.75M | -$8.88M | -$7.79M |
| EPS, basic | -$0.98 | -$1.28 | -$1.46 |
| EPS, diluted | -$0.98 | -$1.28 | -$1.46 |
| Diluted shares | 29.3M | 7.0M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $269.8K | $5.53M | $39.0K |
| Current assets | $332.9K | $5.53M | $790.0K |
| Total assets | $6.84M | $5.54M | $798.1K |
| Current liabilities | $11.76M | $4.63M | $24.71M |
| Total liabilities | $11.86M | $4.73M | $24.81M |
| Shareholders' equity | -$6.10M | -$3.27M | -$24.02M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$14.24M | -$7.28M | -$3.01M |
| Capital expenditures | $466.4K | - | - |
| Free cash flow | -$14.70M | - | - |
| Investing cash flow | -$466.4K | - | $1.1K |
| Financing cash flow | $9.44M | $12.78M | $2.87M |
| Stock-based compensation | $4.27M | $268.3K | - |
| Depreciation and amortization | $363.1K | $2.8K | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $6.07M | $7.35M | $8.80M | $3.76M | $2.50M | $1.31M | $870.5K | $1.21M | $396.6K | $361.8K | $1.02M | $454.5K |
| Selling, general and admin | $2.50M | $2.82M | $3.19M | $3.12M | $2.34M | $3.69M | $2.10M | $1.23M | $383.2K | $268.4K | $138.0K | $167.7K |
| Operating income | -$8.58M | -$10.17M | -$11.99M | -$6.88M | -$4.84M | -$5.00M | -$2.97M | -$2.44M | -$779.8K | -$630.2K | -$1.16M | -$622.2K |
| Interest expense | $5.6K | $75.3K | - | - | - | - | $7.6K | $437.8K | $777.7K | $828.8K | $307.5K | $1.35M |
| Net income | -$8.63M | -$10.40M | -$13.46M | -$6.88M | -$4.54M | -$3.88M | -$2.99M | -$2.88M | -$1.56M | -$1.46M | -$1.46M | -$1.97M |
| EPS, basic | -$0.20 | -$0.27 | - | -$0.21 | -$0.19 | -$0.18 | - | -$0.18 | -$0.26 | -$0.25 | - | -$0.38 |
| EPS, diluted | -$0.20 | -$0.27 | - | -$0.21 | -$0.19 | -$0.18 | - | -$0.18 | -$0.26 | -$0.25 | - | -$0.38 |
| Diluted shares | 43.9M | 38.7M | - | 32.0M | 25.1M | 21.2M | - | 15.9M | 6.0M | 6.0M | - | 5.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $205.0K | $917.6K | $269.8K | $1.88M | $2.80M | $2.97M | $5.53M | $1.86M | $94.9K | $100.2K | $39.0K | $16.1K |
| Current assets | $3.64M | $917.6K | $332.9K | $2.32M | $3.55M | $4.10M | $5.53M | $1.97M | $1.34M | $1.04M | $790.0K | - |
| Total assets | $9.90M | $7.30M | $6.84M | $8.95M | $10.31M | $4.25M | $5.54M | $1.98M | $1.34M | $1.05M | $798.1K | - |
| Current liabilities | $20.64M | $16.95M | $11.76M | $4.15M | $3.46M | $3.54M | $4.63M | $2.58M | $28.31M | $26.46M | $24.71M | - |
| Short-term debt | - | - | - | - | - | - | - | - | $250.0K | $100.0K | - | - |
| Total liabilities | $20.74M | $17.05M | $11.86M | $4.25M | $3.56M | $3.64M | $4.73M | $2.68M | $28.41M | $26.56M | $24.81M | - |
| Shareholders' equity | -$11.91M | -$10.82M | -$6.10M | $3.64M | $4.94M | -$4.19M | -$3.27M | -$707.1K | -$27.06M | -$25.51M | -$24.02M | -$22.52M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.53M | -$4.56M | -$3.73M | -$4.71M | -$2.36M | -$3.44M | -$2.37M | -$3.38M | -$881.2K | -$641.7K | -$871.2K | -$876.6K |
| Capital expenditures | - | - | $0 | $0 | $316.4K | $150.0K | - | - | - | - | - | $0 |
| Free cash flow | - | - | -$3.73M | -$4.71M | -$2.68M | -$3.59M | - | - | - | - | - | -$876.6K |
| Investing cash flow | - | - | $0 | $0 | -$292.8K | -$173.6K | - | - | - | - | $19 | $0 |
| Financing cash flow | $4.82M | $5.21M | $2.12M | $3.78M | $2.48M | $1.05M | $6.05M | $5.15M | $875.9K | $703.0K | $894.1K | $843.4K |
| Stock-based compensation | $1.33M | $1.44M | $1.60M | $814.9K | $905.2K | $941.3K | - | - | - | - | - | - |
| Depreciation and amortization | $124.9K | $124.9K | $124.9K | $124.9K | $112.5K | $695 | $1.4K | $0 | - | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.18 | 0.05 | 0.03 | 0.56 | 1.03 | 1.16 | 1.20 | 0.76 | 0.05 | 0.04 | 0.03 | - |
Source: XBRL data OS Therapies Incorporated files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
OSTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| OSTX | - | - | -$39.37M | - | $52.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
OSTX FAQ
4 questionsIs OSTX profitable?
No. OS Therapies Incorporated reported a net loss of $39.37M for the twelve months ended Jun 30, 2026.How much cash and debt does OSTX have?
OS Therapies Incorporated reported $205.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.When did OSTX last report financial results?
The latest statements here come from OS Therapies Incorporated's 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this OSTX financial data come from?
Quantisnow builds these statements from the structured XBRL data OS Therapies Incorporated files with the SEC. It is provided for information only and is not investment advice.